ACVR1 and fibrodysplasia ossificans progressiva: A subsequent study of palovarotene for treatment of FOP was pursued through a single-arm, open-label, phase III trial (MOVE, PVO-1A-301; NCT03312634), which enrolled palovarotene-naive subjects with both the classical ACVR1R206H and other known ACVR1-activating mutations.13